ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis

Abstract

Alemtuzumab is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. In contrast to rare cases of immune-mediated cutaneous vasculitis, systemic vasculitis after alemtuzumab has not yet been described. We report the case of a 29-year-old man with RRMS who developed fever, auricular chondritis, cutaneous vasculitis and life-threatening diffuse alveolar haemorrhage, 12 months after alemtuzumab. Antibodies to myeloperoxidase appeared 9 months after alemtuzumab and were extremely high at the time of vasculitis. Outcome was favourable after glucocorticoids, plasma exchanges and rituximab. Thus, alemtuzumab may induce life-threatening vasculitis in patients treated for RRMS.

Keywords

Alemtuzumab multiple sclerosis

Get full access to this article

View all access options for this article.

References

Coles

Cohen

Fox

, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 2017; 89: 1117–1126.

Garten

Edwards

Lezcano

, et al. Case report: Leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment. Neurology 2017; 88: P5403.

Sauer

Schliep

Manger

, et al. Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2018; 5(5): e488.

Mavrakanas

Bouatou

Samer

, et al. Carbimazole-induced, ANCA-associated, crescentic glomerulonephritis: Case report and literature review. Ren Fail 2013; 35(3): 414–417.

Baker

Herrod

Alvarez-Gonzalez

, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017; 74(8): 961–969.

Schmidt

Williamson

Ashley-Koch

. HLA-DR15 haplotype and multiple sclerosis: A HuGE review. Am J Epidemiol 2007; 165(10): 1097–1109.

Burns

Fisher

, et al. Molecular analysis of HLA class II genes in Goodpasture’s disease. QJM 1995; 88(2): 93–100.